First Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical Trial

Ananda Pharma has dosed the first patient in ACTiON, its Phase 2 trial of MRX1 in chemotherapy-induced peripheral neuropathy (CIPN), a common chemotherapy side effect with no approved treatment. The double-blind, placebo-controlled trial of 92 participants is led by Professor Marie Fallon at the University of Edinburgh